How long does a complete course of Jisandai/Bingtonsha treatment take?

Epclusa is an oral anti-hepatitis C targeted drug compounded by Sofosbuvir and Velpatasvir. It is currently one of the most widely used all-genotype hepatitis C treatment options worldwide. Different from previous treatment models that relied on interferon and ribavirin, Jisandai precisely targets two key enzymes in the life cycle of the HCV virus, fundamentally inhibiting viral replication and rapidly reducing the viral load to undetectable levels. Its therapeutic advantages are not only reflected in the high cure rate, but more importantly, the treatment course is simple, the side effects are small, and it is suitable for a wide range of people.

Usually, a standard third-generation treatment course is for 12 consecutive weeks, 1 tablet (containing 400 mg sofosbuvir + 100 mg velpatasvir) orally taken once a day. In most patients with chronic hepatitis C without cirrhosis or compensated cirrhosis, clinical cure can be achieved with a 12-week course of treatment. For patients without comorbidities and HIV co-infection, this fixed course of treatment has become a standard recommendation. However, if the patient has decompensated cirrhosis, previous antiviral treatment failure, or other underlying diseases, doctors may combine ribavirin in the treatment or extend the course of treatment, but this requires individualized evaluation.

Another major advantage of Jisandai is that it has an inhibitory effect on all six major genotypes of hepatitis C (GT1~GT6), especially in types 3, 4, 5 and 6 that are difficult to treat with traditional methods. Therefore, it is called a "full-genotype pan-gene treatment program." This also means that most patients no longer need to undergo genotyping tests when receiving antiviral treatment for the first time, simplifying the diagnostic process and reducing the economic burden.

During use, it is very important to insist on taking the medicine at a fixed time every day. Do not miss or interrupt the medicine at will, otherwise it may affect the virus clearance rate and increase the risk of drug resistance. After treatment, an HCV RNA test needs to be performed 12 weeks later to confirm whether a sustained virological response (SVR12) has been achieved, which is an important international indicator for the cure of hepatitis C.

Reference: https://www.epclusa.com/